Navigation Links
Idenix Pharmaceuticals to Present at Three Upcoming Investor Conferences
Date:8/31/2011

CAMBRIDGE, Mass., Aug. 31, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), announced today that Idenix management will participate in a panel discussion at Citi's 6th Annual Biotech Day on September 7, 2011 at 10:00 a.m. ET at the Ritz Carlton, Boston, and present corporate overviews at the William Blair Life Sciences Conference on September 7, 2011 at 2:40 p.m. ET at the InterContinental New York Barclay, New York City and the Stifel Nicolaus Healthcare Conference on September 9, 2011 at 8:35 a.m. ET at the Four Seasons, Boston.

The live and archived webcasts of the company presentations can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com. Please log in approximately 5-10 minutes before each event to ensure a timely connection. The archived replay will be available on the Idenix website for two weeks following the conferences.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with chronic hepatitis C infection. For further information about Idenix, please refer to http://www.idenix.com.

Idenix Pharmaceuticals Contacts:
Kelly Barry (617) 995-9033 (media)
Eric Hoffman (617) 224-4485 (investors)


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Idenix to Host Conference Call Discussing Second Quarter and Six Month 2011 Financial Results
2. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results
3. Idenix Pharmaceuticals to Hold an Investor/Analyst Day Event on October 30, 2010
4. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV
7. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock
10. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
11. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... Cynvenio Biosystems, Inc., a leader ... launch of a new breast cancer monitoring study in partnership with Saint Luke’s ... potential for early detection of recurrent breast cancer using LiquidBiopsy and natural killer ...
(Date:8/16/2017)... ... August 16, 2017 , ... Recent studies ... type. Many treatments for specific cancers, such as breast, prostate, or lung, target ... androgen deprivation therapy for advanced prostate cancer. , This therapy limits the ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... U.S. Food and Drug Administration (FDA) inspection at our Dilworth, MN site. The ... was issued. This inspection was conducted as part of a routine Bioresearch Monitoring ...
(Date:8/15/2017)... , Aug. 15, 2017 After spending the past ... support with crowdsourced data collection, GeneFo now offers this platform to ... aligning and amplifying support, adherence, and data collection vis a vis ... foundations mark the successful launch of this offer. ... GeneFo ...
Breaking Biology Technology:
(Date:5/16/2017)... 16, 2017  Veratad Technologies, LLC ( www.veratad.com ), ... and identity verification solutions, announced today they will participate ... May 15 thru May 17, 2017, in ... Trade Center. Identity impacts the lives ... today,s quickly evolving digital world, defining identity is critical ...
(Date:4/24/2017)... WASHINGTON , April 24, 2017 ... counsel and partner with  Identity Strategy Partners, LLP ... "With or without President Trump,s March 6, ... Foreign Terrorist Entry , refugee vetting can be instilled ... refugee resettlement. (Right now, all refugee applications are ...
(Date:4/17/2017)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... 2016 Annual Report on Form 10-K on Thursday April 13, 2017 ... ... Investor Relations section of the Company,s website at http://www.nxt-id.com  under ... http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):